Look, Bavi is a super-charged Avastin with VIRAL applications. The stock is sitting on a powder keg, the pending studies are gasoline, and MOS is the match.
Actually, bavituximab is quite different than Avastin. They are both monoclonal antibodies but their targets are not the same, and their mechanisms of action are very different. They also have a much different side effect profile. I would not say that bavituximab is a super-charged Avastin.